title: Effects of indinavir in a preliminary phase I study on dogs with stage III slenic hemangiosarcoma.
abstract: HIV protease inhibitors are antiretroviral drugs able to prevent production of infectious particles. It has been shown that these protease inhibitors are able to inhibit cancer-promoted angiogenesis in patients affected by Kaposi's sarcoma. A preliminary phase I study on dogs with stage III splenic hemangiosarcoma was designed in order to evaluate the efficacy and toxicity of the protease inhibitor Indinavir to delay the progression of this advanced neoplasm. The results suggest that Indinavir is potentially beneficial in dogs affected by microscopic residual disease.
authors.affiliation: SAFU Department, Regina Elena Cancer Institute, Rome, Italy. info@enricospugnini.net
authors.forename: Enrico P
authors.initials: EP
authors.lastname: Spugnini
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Esposito
authors.forename: Angela M
authors.initials: AM
authors.lastname: Groeger
authors.forename: Roberto
authors.initials: R
authors.lastname: Cassandro
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Onori
authors.forename: Antonio
authors.initials: A
authors.lastname: Chirianni
authors.forename: Alfonso
authors.initials: A
authors.lastname: Baldi
mesh_terms: D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy* / Q000378:metabolism; D004285:Dogs; D016222:Fibroblast Growth Factor 2 / Q000096:biosynthesis; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006394:Hemangiosarcoma / Q000188:drug therapy* / Q000378:metabolism / Q000662:veterinary; D019469:Indinavir / Q000627:therapeutic use*; D013160:Splenic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000662:veterinary; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis
chemical_list: D017320:HIV Protease Inhibitors; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; D019469:Indinavir